Literature DB >> 3880925

Isolation, experimental transmission, and characterization of causative agent of Potomac horse fever.

C J Holland, M Ristic, A I Cole, P Johnson, G Baker, T Goetz.   

Abstract

Potomac horse fever, a disease characterized by fever, anorexia, leukopenia, and occasional diarrhea, is fatal in approximately 30 percent of affected animals. The seasonal occurrence of the disease (June to October) and evidence of antibodies to the rickettsia Ehrlichia sennetsu in the serum of convalescing horses suggested that a related rickettsia might be the causative agent. Such an agent was isolated in cultured blood monocytes from an experimentally infected pony. This intracytoplasmic organism was adapted to growth in primary cultures of canine blood monocytes. A healthy pony inoculated with these infected monocytes also developed the disease. The organism was reisolated from this animal which, at autopsy, had pathological manifestations typical of Potomac horse fever. Cross serologic reactions between the newly isolated agent and antisera to 15 rickettsiae revealed that it is related to certain members of the genus Ehrlichia, particularly to Ehrlichia sennetsu. Since the disease occurs in other parts of the United States as well as in the vicinity of the Potomac River, and since it has also been reported in Europe, the name equine monocytic ehrlichiosis is proposed as being more descriptive.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3880925     DOI: 10.1126/science.3880925

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  44 in total

1.  Comparison of PCR and culture to the indirect fluorescent-antibody test for diagnosis of Potomac horse fever.

Authors:  J Mott; Y Rikihisa; Y Zhang; S M Reed; C Y Yu
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Passive transfer of antibody to Ehrlichia risticii protects mice from ehrlichiosis.

Authors:  P S Kaylor; T B Crawford; T F McElwain; G H Palmer
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

Review 3.  An overview of research on ehrlichiosis.

Authors:  M Ristic; C J Holland; M Khondowe
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

4.  Association of deficiency in antibody response to vaccine and heterogeneity of Ehrlichia risticii strains with Potomac horse fever vaccine failure in horses.

Authors:  S K Dutta; R Vemulapalli; B Biswas
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

5.  Serologic testing for human granulocytic ehrlichiosis at a national referral center.

Authors:  J A Comer; W L Nicholson; J G Olson; J E Childs
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

6.  Production and characterization of Ehrlichia risticii, the agent of Potomac horse fever, from snails (Pleuroceridae: Juga spp.) in aquarium culture and genetic comparison to equine strains.

Authors:  G H Reubel; J E Barlough; J E Madigan
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

7.  Enzyme-linked immunosorbent assay for Potomac horse fever disease.

Authors:  C I Pretzman; Y Rikihisa; D Ralph; J C Gordon; S Bech-Nielsen
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

8.  Cytopathic effect, plaque formation, and lysis of Ehrlichia chaffeensis grown on continuous cell lines.

Authors:  P Brouqui; M L Birg; D Raoult
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Analysis of complete genome sequence of Neorickettsia risticii: causative agent of Potomac horse fever.

Authors:  Mingqun Lin; Chunbin Zhang; Kathryn Gibson; Yasuko Rikihisa
Journal:  Nucleic Acids Res       Date:  2009-08-06       Impact factor: 16.971

10.  Diagnostic application of polymerase chain reaction for detection of Ehrlichia risticii in equine monocytic ehrlichiosis (Potomac horse fever).

Authors:  B Biswas; D Mukherjee; B L Mattingly-Napier; S K Dutta
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.